Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24678398)

1.

Comment to the article "prevention of B thalassemia in northern Israel - a cost-benefit analysis" by koren et Al.

Amato A.

Mediterr J Hematol Infect Dis. 2014 Mar 9;6(1):e2014021. doi: 10.4084/MJHID.2014.021. eCollection 2014. No abstract available.

2.
3.

Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis.

Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, Shalev S, Blondheim O.

Mediterr J Hematol Infect Dis. 2014 Feb 17;6(1):e2014012. doi: 10.4084/MJHID.2014.012. eCollection 2014.

4.

Cost-benefit analysis of a national thalassaemia prevention programme in Israel.

Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA.

J Med Screen. 1998;5(3):120-6.

PMID:
9795870
5.

Sickle cell anemia in northern Israel: screening and prevention.

Koren A, Zalman L, Palmor H, Zamir RB, Levin C, Openheim A, Daniel-Spiegel E, Shalev S, Filon D.

Isr Med Assoc J. 2009 Apr;11(4):229-34.

6.
7.

Cost-effectiveness of nonsteroidal antiinflammatory drug strategies: comment on the article by Spiegel et al.

Loyd M, Jacobs P, Rublee D.

Arthritis Rheum. 2006 Apr 15;55(2):338-9; author reply 339-40. No abstract available.

8.

Streptococcus group B isolates in a regional hospital area.

Nitzan Y, Maayan M, Wajsman C.

Med Microbiol Immunol. 1980;169(1):21-30.

PMID:
7007849
9.

Comment on the article by Helewa et al.

Rigby AS.

Arthritis Rheum. 1990 Nov;33(11):1751-2. No abstract available.

PMID:
2122904
10.

The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.

Boers M.

Arthritis Rheum. 2009 Nov 15;61(11):1616-7; author reply 1617-8. doi: 10.1002/art.24821. No abstract available.

11.
12.

Comment on 'Red cell alloantibodies in patients with thalassemia' (Spanos et al.)

Michail-Merianou V.

Vox Sang. 1992;62(3):190. No abstract available.

PMID:
1609522
13.

Creating a care-effective cost-effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by Kremer et al.

Newman ED, Harrington TM, Perruquet JL, Davis DE, Torretti D.

Arthritis Rheum. 1995 Feb;38(2):297-8. No abstract available.

PMID:
7848325
14.

Cost-benefit analysis of a thalassemia disease prevention program.

Ostrowsky JT, Lippman A, Scriver CR.

Am J Public Health. 1985 Jul;75(7):732-6.

15.

Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.

Ginsberg GM, Kassis I, Dagan R.

J Epidemiol Community Health. 1993 Dec;47(6):485-90.

16.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

17.
18.

Alcoholism treatment and the importance of economic analysis: comment on Holder et al.

Zarkin GA.

Addiction. 2000 Dec;95(12):1868-9. No abstract available.

PMID:
11218368
19.

Prospective cost-utility analysis of lung transplantation in The Netherlands: a comment on the pilot study by Gartner et al.

van Enckevort PJ, TenVergert EM, Geertsma A, van der Bij W, de Boer WJ, Rutten FF.

J Heart Lung Transplant. 1999 May;18(5):496-7. No abstract available.

PMID:
10363696
20.

Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al and the letter by Senécal et al.

Maillefert JF, Tavernier C, Sibilia J, Vignon E.

Arthritis Rheum. 2000 Feb;43(2):468-9. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk